Home

CELGENE CORP /DE/

CIK 816284 · last filed 2020-07-13

CELGENE CORP /DE/ is a corporate insider who has filed 20 SEC Form 4 insider transactions across 7 companies since 2013. The most recent filing, for XLRN, was dated Jul 13, 2020. Across all open-market trades the lifetime net is +$764.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $228.6M across reported positions. The firm reports its address in Summit, NJ. 110 SEC filings were submitted jointly with ROBERT J HUGIN.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$228.65M

Companies

7

Total Filings

20

Lifetime Open-Market Net

$764.92M

Filer Profile

Reported Address
86 MORRIS AVENUE
SUMMIT, NJ 07901
Phone
(908) 673-9000
State of Incorporation
DE
Related Filers
ROBERT J HUGIN — 110 joint filings, latest 2018-01-31
GILLA KAPLAN — 68 joint filings, latest 2018-05-21
MICHAEL D CASEY — 67 joint filings, latest 2019-11-22
ERNEST MARIO — 64 joint filings, latest 2019-11-22
Mark J Alles — 56 joint filings, latest 2019-11-22
SOL J BARER — 53 joint filings, latest 2011-01-14
MYERS SQUIBB CO BRISTOL — 50 joint filings, latest 2020-07-13
WALTER L ROBB — 47 joint filings, latest 2011-06-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACCELERON PHARMA INC (XLRN) Delisted 10%+ Owner 7,008,510 $178.75 $1.25B $134.50M 7 2020-07-13
STRO 10%+ Owner 172,620 $16.86 $2.91M $0 1 2018-10-02
AGIO 10%+ Owner 6,718,433 $33.60 $225.74M $618.13M 4 2018-01-31
CRISPR Therapeutics AG (PZRX) Delisted 10%+ Owner 8,727,849 — — $1.29M 3 2017-12-07
Alliqua BioMedical, Inc. (ALQA) Delisted 10%+ Owner 1,223,730 — — $5.00M 3 2017-04-13
GLOBEIMMUNE INC (GBIM) Delisted 10%+ Owner 669,502 — — $4.00M 1 2014-07-08
Epizyme, Inc. (EPZM) Delisted 10%+ Owner 3,267,974 $1.47 $4.80M $2.00M 1 2013-06-06

Recent Filings

20 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-07-13 ACCELERON PHARMA INC (XLRN) Delisted Mixed +73,476 -$26 EDGAR
2020-07-06 ACCELERON PHARMA INC (XLRN) Delisted Buy (P) +216,216 $20.00M EDGAR
2019-01-22 ACCELERON PHARMA INC (XLRN) Delisted Buy (P) +706,206 $30.37M EDGAR
2018-10-02 STRO Conv (C) +1,726,197 $0 EDGAR
2018-01-31 AGIO Buy (P) +3,404,616 $228.11M EDGAR
2018-01-23 AGIO Buy (P) +3,404,616 $228.11M EDGAR
2017-12-07 CRISPR Therapeutics AG (PZRX) Delisted Sell (S) −1,112,446 -$21.12M EDGAR
2017-09-25 ACCELERON PHARMA INC (XLRN) Delisted Buy (P) +745,592 $27.59M EDGAR
2017-04-24 AGIO Buy (P) +2,498,300 $123.67M EDGAR
2017-04-13 Alliqua BioMedical, Inc. (ALQA) Delisted Other (J) +296,277 $0 EDGAR
Showing 1–10 of 20
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.